EUCTR2014-000507-27-NO进行中（未招募）1 期
The Clinical Carbetocin Myocardium Trial - CarbetocinHeart2014
Oslo University Hospital, Division of Emergencies and Critical Care0 个研究点开始时间: 2014年7月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Planned cesarean delivery of single baby
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Cardiac diseases, intolerance to IMPs, placental diseases.
研究者
相似试验
已完成
4 期
The Clinical Carbetocin Myocardium TrialPregnancyNCT02528136Oslo University Hospital40
已完成
4 期
Carbetocin Myocardium Trial 2014 Part 2Pregnancy ComplicationsNCT03899961Oslo University Hospital240
已完成
4 期
Cardiovascular Effects of Carbetocin Given During Elective CesareanEffect of Carbetocin on Cardiovascular SystemPregnancyNCT02636816University of British Columbia57
进行中（未招募）
不适用
Evaluation of optimal treatment combination of bevacizumab in combination with gemcitabine/carboplatin or pegylated liposomal doxorubicin/carboplatin in patients with platin-sensitive recurrent ovarian cancer.Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.MedDRA version: 18.1Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004125-24-BEAGO Research GmbH654
进行中（未招募）
1 期
Evaluation of optimal treatment combination of bevacizumab in combination with gemcitabine/carboplatin or pegylated liposomal doxorubicin/carboplatin in patients with platin-sensitive recurrent ovarian cancer.EUCTR2012-004125-24-DEAGO Research GmbH654